Cargando…

Comparative Immunogenicity of HIV-1 Clade C Envelope Proteins for Prime/Boost Studies

BACKGROUND: Previous clinical efficacy trials failed to support the continued development of recombinant gp120 (rgp120) as a candidate HIV vaccine. However, the recent RV144 HIV vaccine trial in Thailand showed that a prime/boost immunization strategy involving priming with canarypox vCP1521 followe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Douglas H., Winters-Digiacinto, Peggy, Mitiku, Misrach, O'Rourke, Sara, Sinangil, Faruk, Wrin, Terri, Montefiori, David C., Berman, Phillip W.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920315/ https://www.ncbi.nlm.nih.gov/pubmed/20711452 http://dx.doi.org/10.1371/journal.pone.0012076

Ejemplares similares

P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies
por: Berman, P, et al.
Publicado: (2009)

Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens
por: Mesa, Kathryn A., et al.
Publicado: (2019)

Gene editing in CHO cells to prevent proteolysis and enhance glycosylation: Production of HIV envelope proteins as vaccine immunogens
por: Li, Sophia W., et al.
Publicado: (2020)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting
por: Cheng, Cheng, et al.
Publicado: (2019)

Broad Antibody Mediated Cross-Neutralization and Preclinical Immunogenicity of New Codon-Optimized HIV-1 Clade CRF02_AG and G Primary Isolates
por: Agwale, Simon M., et al.
Publicado: (2011)

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
por: Hoffenberg, S, et al.
Publicado: (2012)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
por: Karasavvas, N, et al.
Publicado: (2012)

Antigen processing sites in gp120 are conserved across HIV virus clades
por: Yu, B, et al.
Publicado: (2012)

Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization
por: Hogan, Michael J., et al.
Publicado: (2018)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Glycans Flanking the Hypervariable Connecting Peptide between the A and B Strands of the V1/V2 Domain of HIV-1 gp120 Confer Resistance to Antibodies That Neutralize CRF01_AE Viruses
por: O’Rourke, Sara M., et al.
Publicado: (2015)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost
por: Levine, Min Z., et al.
Publicado: (2019)

A Directed Molecular Evolution Approach to Improved Immunogenicity of the HIV-1 Envelope Glycoprotein
por: Du, Sean X., et al.
Publicado: (2011)

Glycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials
por: Yu, Bin, et al.
Publicado: (2012)

HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees
por: Yates, Nicole L., et al.
Publicado: (2018)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
por: Yu, B, et al.
Publicado: (2012)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines
por: Wang, Shixia, et al.
Publicado: (2017)

Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity?
por: Pettini, Elena, et al.
Publicado: (2021)

Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing Antibodies
por: Hutchinson, Jennie M., et al.
Publicado: (2019)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains
por: Wang, Shixia, et al.
Publicado: (2023)

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost
por: Apostólico, Juliana de Souza, et al.
Publicado: (2016)

Development of a Stable MGAT1(−) CHO Cell Line to Produce Clade C gp120 With Improved Binding to Broadly Neutralizing Antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate
por: Narayan, Kristin M., et al.
Publicado: (2013)

Novel Prophylactic Vaccine Using a Prime-Boost Method and Hemagglutinating Virus of Japan-Envelope against Tuberculosis
por: Okada, Masaji, et al.
Publicado: (2011)

P19-14. Recombinant alphavirus replicon particles as a platform to evaluate immunogenicity of early transmitted clade C virus envelopes
por: Franti, M, et al.
Publicado: (2009)

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
por: Fournillier, Anne, et al.
Publicado: (2013)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies
por: Doran, Rachel C., et al.
Publicado: (2018)

A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies
por: Calado, Rita, et al.
Publicado: (2020)

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
por: Harari, Alexandre, et al.
Publicado: (2008)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Heterologous DNA prime-protein boost immunization with RecA and FliD offers cross-clade protection against leptospiral infection
por: Raja, Veerapandian, et al.
Publicado: (2018)

Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection
por: Van Reeth, Kristien, et al.
Publicado: (2017)

Phylodynamics of HIV-1 from a Phase-III AIDS Vaccine Trial in North America
por: Pérez-Losada, Marcos, et al.
Publicado: (2010)

P19-42. Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-envelope glycoproteins
por: Sellhon, G, et al.
Publicado: (2009)

Stepwise Conformational Stabilization of a HIV-1 Clade C Consensus Envelope Trimer Immunogen Impacts the Profile of Vaccine-Induced Antibody Responses
por: Hauser, Alexandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mfqlpj638309o8lst0dbvrdr4e